Optimal control for HIV-1 multi-drug therapy

References

• Adams , B. M. , Banks , H. T. , Tran , H. T. and Kwon , H. 2004 . Dynamic Multidrug Therapies For HIV: Optimal and STI Control Approaches . JBE , 1 ( 2 ) : 223 – 241 .
   Google Scholar
• AIDSinfo . The HIV Life Cycle: A Service of the U.S. Department of Health and Human Services Available at http://aidsinfo.nih.gov
   Google Scholar
• Altes , H. K. , Price , D. A. and Jansen , V. A.A. 2001 . Effector cytotoxic T Lymphocyte numbers induced by vaccination should exceed levels in chronic infection for protection from HIV . Science , 20 : 3 – 6 .
   Google Scholar
• Briz , V. , Poveda , E. and Soriano , V. 2006 . HIV entry inhibitors: Mechanisms of action and resistance pathways . J. Antimicrob. Chemother. , 57 : 619 – 627 .
   PubMed Web of Science ®Google Scholar
• Culshaw , R. V. , Ruan , S. and Spiteri , R. J. 2004 . Optimal HIV treatment by maximising immune response . J. Math. Biol. , 48 : 545 – 562 .
   PubMed Web of Science ®Google Scholar
• Dixit , N. M. and Perelson , A. S. 2004 . Complex patterns of viral decay under antiretroviral therapy: Influence of Pharmacokinetics and intracellular delay . J. Theor. Biol. , 226 : 95 – 109 .
   PubMed Web of Science ®Google Scholar
• Fister , K. R. , Lenhart , S. and McNally , J. S. 1998 . Optimizing chemotherapy in an HIV Model . EJDE , 32 : 1 – 12 .
   Google Scholar
• Fleming , W. H. and Rishel , R. W. 1975 . Deterministic and Stochastic Optimal Control , New York : Springer .
   Google Scholar
• Garira , W. , Musekwa , S. D. and Shiri , T. 2005 . Optimal control of combined therapy in a single strain HIV-1 model . EJDE , 52 : 1 – 22 .
   Google Scholar
• Greenberg , M. L. and Cammack N , N. 2004 . Resistance to enfurvirtide, the first HIV fusion inhibitor . J. Antimicrob. Chemother. , 54 : 333 – 340 .
   PubMed Web of Science ®Google Scholar
• Ho , D. D. , Neumann , A. U. , Perelson , A. S. , Chen , W. , Leonard , J. M. and Markowitz , M. 1995 . Rapid turnover of plasma virions and CD4 lymphocytes . Nature , 373 : 123
   PubMed Web of Science ®Google Scholar
• Janeway , A. C. , Travers , P. , Walport , M. and Shlomchik , J. M. 2005 . IMMUNO BIOLOGY: The Immune System in Health and Disease , New York, , USA : Garland Science Publishing .
   Google Scholar
• Joly , M. and Pinto , J. M. 2006 . Role of mathematical modeling on the optimal control of HIV-1 pathogenesis . AIChE J. , 52 ( 3 ) : 856 – 884 .
   Web of Science ®Google Scholar
• Joshi , H. R. 2002 . Optimal control of an HIV immunology model . Optin. Control Appl. Method, , 23 : 199 – 213 .
   Web of Science ®Google Scholar
• Karrakchou , J. , Rahik , M. and Gourari , S. 2006 . Optimal control and infectiology: Application to an HIV/AIDS model . Appl. Math. Comput. , 177 : 807 – 818 .
   Google Scholar
• Kaufmann , H. E. and Schaible , E. U. A dangerous liaison between two major killers: Mycobacterium tuberculosis and HIV target dendritic cells through DC-SIGN: Commentary . J. Exp. Med. , Availabel at www.jem.org/cgi
   Google Scholar
• Khalili , S. and Armaou , A. 2008 . Sensitivity analysis of HIV infection response to treatment via stochastic modeling . Chem. Eng. Sci. , 63 ( 5 ) : 1330 – 1341 .
   Google Scholar
• Kirschner , D. 1996 . Using mathematics to understanding HIV immune dynamics . Not. AIMS , 43 : 191 – 202 .
   Google Scholar
• Kirschner , D. and Wedd , G. F. 1997 . A mathematical model of combined drug therapy of HIV infection . J. Theor. Med. , 1 : 25 – 34 .
   Google Scholar
• Kirschner , D. and Webb , G. F. 1997 . Understanding drug resistance for monotherapy treatment of HIV infection . Bull. Math. Biol. , 59 : 763 – 785 .
   PubMed Web of Science ®Google Scholar
• Klenerman , P. , Wu , Y. and Philips , R. 2002 . HIV: Current opinion on escapology . Curr. Opin. Microbiol. , 5 : 408 – 413 .
   Google Scholar
• Kwon , H. 2001 . Optimal treatment strategies derived from a HIV model with drug resistant mutants . Appl. Math. Comput. , 188 ( 2 ) : 1193 – 1204 .
   Google Scholar
• Lalezari , J. P. , Henry , K. , O'Hean , M. , Montaner , J. S. , Piliero , P. J. and Trottier , B. 2003 . Enfuvirtide, an HIV-1 Fusion Inhibitor, for Drug-Resistant HIV Infection in North and South America . N. Eng. J. Med. , 348 : 2175 – 85 .
   PubMed Web of Science ®Google Scholar
• Lever , N. L. 1996 . The Molecular Biology of HIV/AIDS , New York : John Wiley and Sons .
   Google Scholar
• Magombedze , G. , Garira , W. and Mwenje , E. 2008 . In-vivo mathematical study of co-infection dynamics of HIV-1 and Mycobacterium tuberculosis . J. Biol. Sys. , 16 ( 3 ) : 357 – 394 .
   Google Scholar
• Magombedze , G. , Garira , W. and Mwenje , E. 2008 . Modelling the immuno-pathogenesis of HIV-1 infection and the effect of multi-drug therapy: The role of Fusion inhibitors in HAART . Math. Biosci. Eng. , 5 ( 3 ) : 485 – 504 .
   PubMed Web of Science ®Google Scholar
• Mohri , H. , Bonhoeffer , S. , Monard , S. , Perelson , A. S. and Ho , D. D. 1998 . Rapid turnover of T-lymphocytes in SIV-infected rhesus macaques . Science , 279 : 1223
   PubMedGoogle Scholar
• Moore , J. P. and Doms , R. W. 2003 . The entry of entry inhibitors: A fusion of science and medicine . PNAS , 100 ( 19 ) : 10598 – 10602 .
   PubMed Web of Science ®Google Scholar
• Moyle , G. 2003 . Stopping HIV fusion with enfuvirtide: The first step to extracellular HAART . J. Antimicrob. Chemother. , 51 : 213 – 217 .
   PubMed Web of Science ®Google Scholar
• Pontryagin , L. S. , Boltyanskii , V. T. , Gamkrelidze , R. V. and Mishcheuko , E. F. 1896 . The Mathematical Theory of Optimal Processes , Vol. 4 , New York : Gordon and Breach Science Publishers .
   Google Scholar
• Rockstroh , J. K. and Mauss , S. 2004 . Clinical perspective of fusion inhibitors for treatment of HIV . J. Antimicrob. Chemother. , 53 : 700 – 702 .
   PubMedGoogle Scholar
• Sewell , A. K. , Price , D. A. , Oxenius , A. , Keller , A. D. and Phillips , R. F. 2000 . Cytotoxic T lymphocyte responses to human immunodeficiency virus: Control and escape . Stem Cells , 18 : 230 – 244 .
   Google Scholar
• Shim , H. , Han , S. J. , Chung , C. C. , Nam , S. and Seo , J. M. 2003 . Optimal scheduling of drug treatment for HIV infection: Continuous dose control of the chemotherapy and receding horizon control . Int. J. Control Autom. Syst. , 1 ( 3 ) : 401 – 407 .
   Google Scholar
• Shiri , T. , Garira , W. and Musekwa , S. D. 2005 . A two-Strain HIV-1 mathematical model to assess the effects of chemotherapy on disease parameters . Math. Biosci. Eng. , 2 : 811 – 832 .
   PubMed Web of Science ®Google Scholar
• Stevenson , M. 2003 . HIV-1 pathogenesis: REVIEW . Nat. Med. , 9 : 7
   Google Scholar
• Tashima , K. T. and Carpenter , C. C.J. 2003 . Fusion Inhibition A Major but costly step Forward in the Treatment of HIV-1 . N. Engl. J. Med. , 348 ( 22 ) : 2249 – 2250 .
   PubMed Web of Science ®Google Scholar
• Wei , X. , Ghost , S. K. , Taylor , M. E. , Jahnson , V. A. , Emini , E. A. , Deutsch , P. , Lifson , J. D. , Bonhoeffer , S. , Nowak , M. A. and Hah , B. H. 1995 . Viral dynamics in human immunodeficiency virus type 1 infection . Nature , 373 : 117
   PubMed Web of Science ®Google Scholar
• Wodarz , D. and Nowak , M. A. 1999 . Specific Therapy Regimens Could Lead to Long-term Immunological Control of HIV PNAS . 96 ( 25 ) : 14464 – 14469 .
   Google Scholar
• Wodarz , D. and Nowak , M. A. 2000 . Immune responses and viral phenotype: Do replication rate and cytopathicity influence virus load? . J. Theor. Med. , 2 : 113 – 127 .
   Google Scholar
• Wodarz , D. , Sierro , S. and Klenerman , P. 2007 . Dynamics of killer T cell inflation in viral infections . J. R. Soc. Interface , 4 : 533 – 543 .
   Google Scholar
• Zurakowski , R. and Teel , A. R. 2006 . A model predictive control based scheduling method for HIV therapy . J. Theor. Biol. , 238 ( 2 ) : 368 – 382 .
   Google Scholar